NCT01949662View on ClinicalTrials.gov

Haloperidol and Lorazepam for Delirium in Patients With Advanced Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

93

Participants

Timeline

Start Date

January 31, 2014

Primary Completion Date

August 26, 2016

Study Completion Date

January 1, 2026

Conditions
Advanced Cancers
Interventions
DRUG

Lorazepam

3 mg by vein one time only.

DRUG

Placebo

Placebo consisting of preservative free 0.9% normal saline given one time by vein.

DRUG

Haloperidol decanoate

8 mg/day by vein.

BEHAVIORAL

Questionnaires

Questionnaire completion at baseline, and every day while participant is in the palliative care unit. These questions will take about 20 minutes to complete.

Trial Locations (1)

77030

University of Texas MD Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER